These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 360685)

  • 1. [Aminalon as an agent for the prevention of motion sickness].
    Lapaev EV; Voinova II; Vorob'ev OA; Barmicheva NM
    Zh Ushn Nos Gorl Bolezn; 1978; (5):35-9. PubMed ID: 360685
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevention of motion sickness with selegilinum hydrochloricum.
    Bodó G; Elkán K; Bencze G
    Ther Hung; 1989; 37(2):103-6. PubMed ID: 2511643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of the effectiveness of drugs for prevention of motion sickness].
    Galle RR; Gusakova GA; Sabaev VV; Galle NN
    Kosm Biol Aviakosm Med; 1988; 22(4):90-4. PubMed ID: 3066982
    [No Abstract]   [Full Text] [Related]  

  • 4. [Prevention and treatment of the symptom complex in motion sickness].
    Esipov IA
    Voen Med Zh; 1973 Feb; 2():69-71. PubMed ID: 4765549
    [No Abstract]   [Full Text] [Related]  

  • 5. Phenytoin for motion sickness: clinical evaluation.
    Knox GW; Woodard D; Chelen W; Ferguson R; Johnson L
    Laryngoscope; 1994 Aug; 104(8 Pt 1):935-9. PubMed ID: 8052077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a new antinauseant drug for the prevention of motion sickness.
    Graybiel A; Knepton J
    Aviat Space Environ Med; 1977 Sep; 48(9):867-71. PubMed ID: 334151
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of phenytoin in the prevention of motion sickness.
    Chelen W; Kabrisky M; Hatsell C; Morales R; Fix E; Scott M
    Aviat Space Environ Med; 1990 Nov; 61(11):1022-5. PubMed ID: 2256875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind placebo controlled evaluation of acupressure in the treatment of motion sickness.
    Warwick-Evans LA; Masters IJ; Redstone SB
    Aviat Space Environ Med; 1991 Aug; 62(8):776-8. PubMed ID: 1930060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind placebo controlled study of cinnarizine in the prophylaxis of seasickness.
    Hargreaves J
    Practitioner; 1980 May; 224(1343):547-50. PubMed ID: 6999486
    [No Abstract]   [Full Text] [Related]  

  • 10. [Antiepileptic drugs in the combined medicinal prevention of motion sickness].
    Karkishchenko NN; Dimitriadi NA
    Kosm Biol Aviakosm Med; 1991; 25(1):21-3. PubMed ID: 2046293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcium antagonists in the prevention of motion sickness.
    Lee JA; Watson LA; Boothby G
    Aviat Space Environ Med; 1986 Jan; 57(1):45-8. PubMed ID: 3510617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there a role for nonsedating antihistamines in motion sickness? Fallout from space research may soon benefit your patients.
    Kohl RL
    J Respir Dis; 1991 Apr; 12(4 Suppl):S17-21. PubMed ID: 11542203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arousal and stability: the effects of five new sympathomimetic drugs suggest a new principle for the prevention of space motion sickness.
    Kohl RL; Calkins DS; Mandell AJ
    Aviat Space Environ Med; 1986 Feb; 57(2):137-43. PubMed ID: 3513752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of overt motion sickness by incremental exposure to otherwise highly stressful coriolis accelerations.
    Graybiel A; Deane FR; Colehour JK
    Aerosp Med; 1969 Feb; 40(2):142-8. PubMed ID: 5304382
    [No Abstract]   [Full Text] [Related]  

  • 15. Prevention of overt motion sickness by incremental exposure to otherwise highly stressful Coriolis accelerations. NAMI-1044.
    Graybiel A; Deane FR; Colehour JK
    NASA Contract Rep NASA CR; 1968 May; ():1-13. PubMed ID: 5303710
    [No Abstract]   [Full Text] [Related]  

  • 16. Mechanisms of antimotion sickness drugs.
    Wood CD; Manno JE; Wood MJ; Manno BR; Redetzki HM
    Aviat Space Environ Med; 1987 Sep; 58(9 Pt 2):A262-5. PubMed ID: 3675502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectivity of antimotion sickness drugs during artificial gravity simulations.
    Green JA
    Aerosp Med; 1973 Nov; 44(11):1255-60. PubMed ID: 4586812
    [No Abstract]   [Full Text] [Related]  

  • 18. [Use of a method of electrotranquilizing for increasing human vestibular resistance].
    Mel'nik SG; Shakula AV; Ivanov VV
    Voen Med Zh; 1986 Aug; (8):42-5. PubMed ID: 3490051
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of phosphatidylcholine in the modulation of motion sickness susceptibility.
    Kohl RL; Ryan P; Homick JL
    Aviat Space Environ Med; 1985 Feb; 56(2):125-8. PubMed ID: 3985888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative assessment of vestibular, optokinetic, and optovestibular stimulation in the development of experimental motion sickness.
    Matsnev EI; Kuz'min MP; Zakharova LN
    Aviat Space Environ Med; 1987 Oct; 58(10):954-7. PubMed ID: 3499890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.